Articles related to VISION LOSS

A young child with an inherited tumor-predisposition syndrome develops recurrent bilateral visual decline after completing first-line chemotherapy for a radiographically diagnosed optic pathway tumor, requiring reassessment of treatment urgency, systemic options, and surveillance.

A systematic review of reported vision loss cases following nonsurgical rhinoplasty found that visual impairment was typically immediate and often irreversible despite treatment. The findings highlight a rare but severe complication associated with cosmetic dermal filler injections.

A systematic review and meta-analysis linked plasma exchange with high recovery rates in MOGAD attacks, especially optic neuritis. Included studies were observational and could not isolate PLEX effects.

A Swedish register-based cohort associated GLP-1 receptor agonist use with higher relative risk of anterior ischemic optic neuropathy. Absolute event rates were low, and findings attenuated after diabetes-severity controls.

University of Oklahoma researchers identified a photoreceptor lysosomal recycling pathway regulated by PIKfyve. Mouse-model disruption produced photoreceptor degeneration and RPE changes resembling macular degeneration biology.

Ocular Therapeutix announced FDA alignment on a planned fourth-quarter 2026 NDA submission for Axpaxli in wet AMD, based on SOL-1 phase 3 efficacy data and interim safety results from the ongoing SOL-R trial.